Onco-Summaries: Daily Oncology Updates at a Glance

24/03/2026

---

• The Ph3 SENTRY trial of Karyopharm's selinexor + ruxolitinib met SVR35 but not Abs-TSS endpoint in frontline myelofibrosis

  
  

• ReCerise's RCT1213 received the FDA ODD for hepatocellular carcinoma

---

The Ph3 SENTRY trial of Karyopharm's selinexor + ruxolitinib met SVR35 but not Abs-TSS endpoint in frontline myelofibrosis (Ref)

Karyopharm Therapeutics reported topline results from its Phase 3 SENTRY trial of selinexor 60 mg + ruxolitinib in frontline myelofibrosis.

• The trial met the first co-primary endpoint of SVR35. Rapid, deep and sustained spleen volume reduction rates were seen in the combination arm

• Abs-TSS at week 24 relative to baseline was comparable across the two arms with similar symptom improvement relative to baseline; the difference across the two arms was not statistically significant

• Topline results suggested a promising signal in OS for the combination arm

Return to Top

ReCerise's RCT1213 received the FDA ODD for hepatocellular carcinoma (Ref)

The US FDA granted the orphan drug designation to ReCerise Therapeutics' RCT1213 (anti-TM4SF5) for hepatocellular carcinoma (HCC).

• Kim Yong-bae, CEO, ReCerise: “This FDA Orphan Drug Designation reflects recognition of RCT1213’s development potential. We aim to advance RCT1213 through global clinical development and partnerships.”

  
  

Return to Top